Interview with Martin Nelzow, CEO, Boehringer Ingelheim Brazil
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Address: Rochaverá Corporate Towers. Av. Nações Unidas, 14.171 – Torre Marble – 18º andar – São Paulo – SP. CEP: 04794-000
Tel: (11) 4949-4700
Web: http://www.boehringer-ingelheim.com.br/principal.asp
The Boehringer Ingelheim group is one of the top 20 pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, operates globally with 138 affiliates in 47 countries and 41,300 employees. Since its founding in 1885, this family business is committed to researching, developing and marketing novel products of high therapeutic value for human and veterinary medicine.
Present in Brazil since 1956, headquartered in Sao Paulo and factory in Itapecerica da Serra (SP), the company employs approximately 1,000 employees and sells products with brands like Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton , and several prescription products, with an outstanding performance in the areas respiratory, cardiovascular, Parkinson’s and others.
Located in Itapecerica da Serra, São Paulo, the Brazilian plant has excellence in the manufacture of medicines and is one of the largest and most modern of the group in the world, accounting for the 3rd largest production volume, representing 10% of the company’s global . Through its Industrial Business Area, the plant of Boehringer Ingelheim in Brazil also produces products for other laboratories.
Since 1998, Boehringer Ingelheim has been designated by the Great Place to Work Institute as one of the 100 best companies to work in Brazil. In total, there have been nine nominations, eight of them consecutive. Since 2004 the company has also been designated by the Great Place to Work as one of the best companies to work in Latin America.
Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
After international tenures in Korea and at Servier’s global headquarters in Paris, Matthieu Mendil has taken the helm of Servier Brazil at a pivotal moment in the affiliate’s evolution. Drawing…
Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s…
Rolf Hoenger discusses Roche LATAM’s growth, emphasising patient-centric strategies, untapped access potential, and evidence-based dialogue with policymakers. He highlights accelerated regulatory approvals, digital health initiatives, and Movement Health Foundation projects,…
Roberto Alvarenga, VP at Biotronik’s Latin American operations, reflects on the company’s six decades of innovation and LatAm’s emergence as the firm’s fastest-growing region. He outlines a strategy focused on…
Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and…
Adium is one of Latin America’s most expansive pharmaceutical groups, operating across 18 countries with a workforce of 7,000 employees. The organisation has unified its brand identity across the region…
Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active…
Sinan Atlig reflects on a 25-year global career spanning Turkey, Colombia, the Middle East, and the US, shaped decisively by vaccine leadership through the COVID-19 era. He identifies vaccines and…
As one of Brazil’s leading pharmaceutical powerhouses, CIMED has redefined what it means to be both national and innovative. Built on a fully verticalised model that spans from R&D to…
Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), discusses the organisation’s evolution from pandemic response to comprehensive health system transformation, regional production capabilities, and the imperative for…
As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the…
Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different…
See our Cookie Privacy Policy Here
